These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 11944823)

  • 1. Cyclization strategies in peptide derived drug design.
    Li P; Roller PP
    Curr Top Med Chem; 2002 Mar; 2(3):325-41. PubMed ID: 11944823
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Backbone-Cyclized Peptides: A Critical Review.
    Rubin SJS; Qvit N
    Curr Top Med Chem; 2018; 18(7):526-555. PubMed ID: 29773062
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Engineering of conotoxins for the treatment of pain.
    Carstens BB; Clark RJ; Daly NL; Harvey PJ; Kaas Q; Craik DJ
    Curr Pharm Des; 2011 Dec; 17(38):4242-53. PubMed ID: 22204425
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recent Reports of Solid-Phase Cyclohexapeptide Synthesis and Applications.
    Prior AM; Hori T; Fishman A; Sun D
    Molecules; 2018 Jun; 23(6):. PubMed ID: 29912160
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Peptidomimetics: Fmoc solid-phase pseudopeptide synthesis.
    Cudic P; Stawikowski M
    Methods Mol Biol; 2008; 494():223-46. PubMed ID: 18726577
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Conformationally restricted thrombin inhibitors resistant to proteolytic digestion.
    Szewczuk Z; Gibbs BF; Yue SY; Purisima EO; Konishi Y
    Biochemistry; 1992 Sep; 31(38):9132-40. PubMed ID: 1390700
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The cyclotides: novel macrocyclic peptides as scaffolds in drug design.
    Craik DJ; Simonsen S; Daly NL
    Curr Opin Drug Discov Devel; 2002 Mar; 5(2):251-60. PubMed ID: 11926131
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synthesis and evaluation of novel 8,5-fused bicyclic peptidomimetic compounds as interleukin-1beta converting enzyme (ICE) inhibitors.
    Soper DL; Sheville JX; O'Neil SV; Wang Y; Laufersweiler MC; Oppong KA; Wos JA; Ellis CD; Baize MW; Chen JJ; Fancher AN; Lu W; Suchanek MK; Wang RL; Schwecke WP; Cruze CA; Buchalova M; Belkin M; Wireko F; Ritter A; De B; Wang D; Demuth TP
    Bioorg Med Chem; 2006 Dec; 14(23):7880-92. PubMed ID: 16908171
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Diminished oligomerization in the synthesis of new anti-angiogenic cyclic peptide using solution instead of solid-phase cyclization.
    Rubio S; Clarhaut J; Péraudeau E; Vincenzi M; Soum C; Rossi F; Guillon J; Papot S; Ronga L
    Biopolymers; 2016 May; 106(3):368-75. PubMed ID: 26832831
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Engineering an Affinity-Enhanced Peptide through Optimization of Cyclization Chemistry.
    Ngambenjawong C; Pineda JM; Pun SH
    Bioconjug Chem; 2016 Dec; 27(12):2854-2862. PubMed ID: 27779387
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rapid and quantitative cyclization of multiple peptide loops onto synthetic scaffolds for structural mimicry of protein surfaces.
    Timmerman P; Beld J; Puijk WC; Meloen RH
    Chembiochem; 2005 May; 6(5):821-4. PubMed ID: 15812852
    [No Abstract]   [Full Text] [Related]  

  • 12. A gold mine for drug discovery: Strategies to develop cyclic peptides into therapies.
    Jing X; Jin K
    Med Res Rev; 2020 Mar; 40(2):753-810. PubMed ID: 31599007
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Melanoma targeting with [
    Carta D; Salvarese N; Morellato N; Gao F; Sihver W; Pietzsch HJ; Biondi B; Ruzza P; Refosco F; Carpanese D; Rosato A; Bolzati C
    Nucl Med Biol; 2016 Dec; 43(12):788-801. PubMed ID: 27694057
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synthesis of linear and cyclic opioid-based peptide analogs containing multiple N-methylated amino acid residues.
    Adamska A; Kolesińska B; Kluczyk A; Kamiński ZJ; Janecka A
    J Pept Sci; 2015 Nov; 21(11):807-10. PubMed ID: 26400609
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A comparative study of backbone versus side chain peptide cyclization: application for HIV-1 integrase inhibitors.
    Hayouka Z; Levin A; Hurevich M; Shalev DE; Loyter A; Gilon C; Friedler A
    Bioorg Med Chem; 2012 May; 20(10):3317-22. PubMed ID: 22507205
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Potent inhibition of protein-tyrosine phosphatase by phosphotyrosine-mimic containing cyclic peptides.
    Akamatsu M; Roller PP; Chen L; Zhang ZY; Ye B; Burke TR
    Bioorg Med Chem; 1997 Jan; 5(1):157-63. PubMed ID: 9043667
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Engineering cyclic peptide toxins.
    Clark RJ; Craik DJ
    Methods Enzymol; 2012; 503():57-74. PubMed ID: 22230565
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cyclic Tetrapeptides from Nature and Design: A Review of Synthetic Methodologies, Structure, and Function.
    Sarojini V; Cameron AJ; Varnava KG; Denny WA; Sanjayan G
    Chem Rev; 2019 Sep; 119(17):10318-10359. PubMed ID: 31418274
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lanthionine-somatostatin analogs: synthesis, characterization, biological activity, and enzymatic stability studies.
    Osapay G; Prokai L; Kim HS; Medzihradszky KF; Coy DH; Liapakis G; Reisine T; Melacini G; Zhu Q; Wang SH; Mattern RH; Goodman M
    J Med Chem; 1997 Jul; 40(14):2241-51. PubMed ID: 9216843
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel method for the synthesis of urea backbone cyclic peptides using new Alloc-protected glycine building units.
    Hurevich M; Tal-Gan Y; Klein S; Barda Y; Levitzki A; Gilon C
    J Pept Sci; 2010 Apr; 16(4):178-85. PubMed ID: 20196085
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.